Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division ... Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States. Show more
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology PR...
2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* 2024 Fourth-Quarter Earnings per share (EPS) of $1.41...
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression PR Newswire TITUSVILLE, N.J., Jan. 21, 2025 Following U.S. FDA...
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer PR...
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of...
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 5.43 | 3.7031985269 | 146.63 | 154.14 | 146.383 | 10292395 | 150.97898378 | CS |
| 4 | 7.9 | 5.48002219756 | 144.16 | 154.14 | 140.68 | 9770004 | 146.94532448 | CS |
| 12 | -5 | -3.18349675283 | 157.06 | 157.58 | 140.68 | 8712615 | 148.81833646 | CS |
| 26 | -7.79 | -4.87331873632 | 159.85 | 168.85 | 140.68 | 7331361 | 155.32376313 | CS |
| 52 | -8.31 | -5.18176716343 | 160.37 | 168.85 | 140.68 | 7395721 | 153.92899056 | CS |
| 156 | -19.44 | -11.3352769679 | 171.5 | 186.69 | 140.68 | 8590000 | 163.12852302 | CS |
| 260 | 2.31 | 1.54257095159 | 149.75 | 186.69 | 109.16 | 8196905 | 159.88289343 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
